Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25065229 | 0.85 | CHRM2 (0.34) | KDM1AEPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL31267867 | 0.85 | CHRM2 (0.34) | KDM1AEPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL30186334 | 0.85 | CHRM2 (0.34) | KDM1AEPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL25065230 | 0.85 | CHRM2 (0.34) | KDM1AEPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL25092596 | 0.82 | EPHX2 (0.32) | KDM1AEPHX2 | |
| SCHEMBL25092593 | 0.82 | EPHX2 (0.32) | KDM1AEPHX2 | |
| SCHEMBL22324273 | 0.80 | — | — | |
| SCHEMBL22214267 | 0.78 | KDM1A (0.39) | KDM1AEPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL25176823 | 0.78 | KDM1A (0.39) | KDM1AEPHX2CHRM2CHRM1CHRM3 | |
| SCHEMBL28484797 | 0.78 | KDM1A (0.39) | KDM1AEPHX2CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101016-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119320388-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-01-17 | — | — | CN | disclosed |
| US-11964971-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230068499-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101016-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | KDM1A 3431/4885EPHX2 2935/4885CHRM2 4693/4885 |
| US-11964971-B2 | Methods and compositions for modulating splicing | RBM17, SF3B1, SF3B5 | KDM1A 3431/4885EPHX2 2935/4885CHRM2 4693/4885 |
| US-20220048902-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | KDM1A 3431/4885EPHX2 2935/4885CHRM2 4693/4885 |
| US-20230068499-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | KDM1A 3431/4885EPHX2 2935/4885CHRM2 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.